Tuesday, September 3, 2013

Brighten Your Dark Spots Without Breaking Your Wallet

http://www.fairskindiva.com/
Brighten Your Dark Spots Without Breaking Your Wallet
At times you have a belief that you can get away with perfect skin. Yet one of the things that will stalk you down the road is dark spots. They can have a bearing on your perfect complexion. With a dedicated skin care routine, they will disappear over time. Yet you certainly need to be patient. Usually reducing these spots doesn't happen overnight.

The appearance of dark spots implies that your skin has too much melanin. What is responsible for triggering the skin to produce excess melanin? When your skin undergoes a trauma or is being exposed to long hours of hot sun, it will shields itself by releasing high amount of melanin in that spot.

If you consult any skin specialist for dark spot elimination, 90% of them will tell you to use hydroquinone. Hydroquinone is very effective as it interferes the synthesis of melanin. Gradually, the skin stops producing excess melanin. In addition, whatever spots on your skin will be hardly noticeable.

Some would advocate the use of alpha hydroxy acids (AHA) as part of the skin care regimen. It helps to eliminate dark spots fast as the cell revival is hastened. Normally in about four weeks, your skin will improve.

You will enjoy better results if you wear sunscreen lotion on top of hydroquinone. You marvel why you still have some blotches after using the treatment. The biggest blunder is not to use sun cream. Hydroquinone by itself is not sufficient to resist the effects of UV rays on melanin production. These rays will encourage the skin to produce melanin constantly. Sun cream can shield your skin from the unhealthy UV rays. It also holds hydroquinone in place.

Monday, September 2, 2013

Not your grandmother's gym class

By Dorene Internicola NEW YORK (Reuters) - Physical education in the United States has come a long way since the one-size-fits-all regimen of jumping jacks and rope climbing that was the bane of the baby boomer generation. Today, where children learn can determine the type of fitness lessons they receive. ... Get the complete story

Debiopharm Group™ Initiates Phase I Dose Escalation Study With Debio 1347 (CH5183284) in Advanced Solid Tumors with FGFR Alterations

Debiopharm Group™ Initiates Phase I Dose Escalation Study With Debio 1347 (CH5183284) in Advanced Solid Tumors with FGFR Alterations

LAUSANNE, Switzerland, September 2, 2013 /PRNewswire/ --

Debiopharm Group (Debiopharm), the Swiss-based global biopharmaceutical company that focuses on the development of prescription drugs that target unmet medical needs including oncology, today announced the start of a phase I, open label multicenter study of a selective FGFR 1, 2, 3 inhibitor, Debio 1347 (CH5183284) in patients with advanced solid tumors.

The aim of the study is to identify the dose limiting toxicity (DLT) and to estimate the maximal tolerated dose (MTD) of Debio 1347 (CH5183284) based on the safety and tolerability of the product during a daily oral administration to patients suffering from advanced solid malignancies that have an alteration of the FGFR 1, 2 or 3 genes (fibroblast growth factor receptor). During an expansion part, the study will also evaluate the safety profile at the recommended dose of Debio 1347 (CH5183284) in a larger cohort of patients.

"We are delighted to initiate this first clinical phase I study with Debio 1347 (CH5183284)," said Rolland-Yves Mauvernay, President and founder of Debiopharm Group. "Debio 1347 (CH5183284) is going to be developed with a companion diagnostic and we believe it could become a personalized treatment option for patients suffering from solid tumors which could significantly improve their outcomes."

In December 2012, Debiopharm signed an exclusive license agreement with Chugai Pharmaceutical Co., Ltd for the development and commercialization of Debio 1347 (CH5183284) in all countries worldwide including Japan. Eight months after executing the deal, Debio 1347 (CH5183284) is being tested in a phase I in several oncology centers of excellence in the USA and Europe.

About Debiopharm Group™

Debiopharm Group™ (Debiopharm) is a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs. The group in-licenses, develops and/or co-develops promising biological and small molecule drug candidates having reached clinical development phases I, II or III, as well as earlier stage candidates. It develops its products for global registration and access to the largest number of patients worldwide. The products are out-licensed to pharmaceutical partners for sales and marketing. Debiopharm is also active in the field of companion diagnostics with a view to progressing in the area of personalized medicine. Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

For more information about Debiopharm Group™, please visit: http://www.debiopharm.com.

Debiopharm International SA Contact    
Beatrice Hirt
Communication Coordinator
beatrice.hirt@debiopharm.com
Tel.: +41(0)21-321-01-11

Additional Media Contacts
In London
Maitland
Brian Hudspith
bhudspith@maitland.co.uk
Tel: +44(0)20-7379-5151

In New York
Russo Partners, LLC
Martina Schwarzkopf, Ph.D.
Account Executive
martina.schwarzkopf@russopartnersllc.com
Tel: +1-212-845-4292

SOURCE The Debiopharm Group


Source: www.prnewswire.com

Music may negatively affect novice drivers

Music may negatively affect novice drivers
A new study argues that novice teenage drivers who 'rock out' to a playlist of favourite tunes may end up with impaired motor skills.

Sunday, September 1, 2013

Cycling For Burning Calories, a Good Exercise

Cycling For Burning Calories, a Good Exercise
You bet it is! Bicycling is one of the advisable workable exercises for perfervid calories. Whether it is on a stationary bike in a gym, at interior or moving outdoors, equation a ride comic much ...

Backstreet Boys To Open 2013 MDA Show Of Strength Telethon Labor Day Weekend

Backstreet Boys To Open 2013 MDA Show Of Strength Telethon Labor Day Weekend

TUCSON, Ariz., Sept. 1, 2013 /PRNewswire-USNewswire/ -- Get ready for a "Larger than Life" performance when the Backstreet Boys open the 48th annual MDA Show of Strength Telethon this Labor Day weekend on Sunday, 9/8c, on ABC television stations across the country.

(Photo: http://photos.prnewswire.com/prnh/20130901/DC72508 )
(Photo: http://photos.prnewswire.com/prnh/20130813/DC63041LOGO )

The multiplatinum group of A. J. McLean, Howie Dorough, Nick Carter, Kevin Richardson and Brian Littrell will perform their newest single "In A World Like This" from their eighth studio album and nationwide tour of the same name. (Click here for Hi Res photos of the Backstreet Boys' performance and exclusive behind-the-scenes telethon shots.)

In addition to their new song, the group will treat the viewing audience to a BSB classic when they launch into one of the most popular hits of their 20-year career, "I Want It That Way."

"Performing at an event like the MDA telethon has a much deeper meaning to us now that we all have families or children of our own," said Brian Littrell. "When I met the families at the show, I made sure to tell them that their children are an inspiration to all of us, and I encouraged them to be strong, and to continue to hold their loved ones close and fight together. We hear that research for many of these diseases is moving at an incredible pace, so we all agree that we'll continue to do our part to help MDA keep moving forward in its search for treatments and cures."

In addition to the Backstreet Boys performance, the 2013 telethon will feature a star-studded celebrity lineup, including: Ryan Seacrest; Paula Abdul; country stars Luke Bryan, Darius Rucker and Lee Ann Womack; Enrique Iglesias; teenage pop sensation Austin Mahone; "Glee" star Matthew Morrison; hip-hop dance crew Jabbawockeez; "American Idol" runner-up Jessica Sanchez; Kenny Loggins with the Blue Sky Riders; American blues rock band Vintage Trouble; and Universal recording artist and star from "The Voice" Chris Mann.

Additional presenters for the 2013 show include: ABC's Dr. Richard Besser; "Dancing with the Stars" contestant and "Brady Bunch" mom Florence Henderson; Emmy award-winning journalist Jann Carl; Olympic gold medal gymnasts Nadia Comaneci and Bart Conner; and No Doubt drummer Adrian Young and his son Mason Young.

About MDA Show of Strength Telethon
The MDA telethon is one of America's longest-standing and beloved fundraising and entertainment events. For 48 years, funds raised by MDA telethons also have contributed to the organization's worldwide research program. Today, through current clinical trials, there is growing excitement that new lifesaving treatments and discoveries are on the horizon for many of the disorders MDA is dedicated to defeating, including Duchenne muscular dystrophy (DMD), spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS).          

As in the past, the entertainment event will raise funds and awareness to support MDA's mission to help children and adults affected by progressive and often fatal muscle diseases.

While the telethon has consistently enjoyed robust support from some of the biggest celebrities in show business, the real stars on the telethon are the individuals and families served by MDA.

MDA's first Labor Day weekend telethon was broadcast in 1966 on a single New York station and has become the most successful fundraising event in the history of television. The show, with Jerry Lewis as its iconic host through 2010, and with help from a legion of top celebrities and entertainers, has raised millions each year to provide life-enhancing support and services for the families MDA serves.

Visit mda.org/muscle to learn more about the 2013 MDA telethon.

About MDA
The Muscular Dystrophy Association is the world's leading nonprofit health agency dedicated to finding treatments and cures for muscular dystrophy, amyotrophic lateral sclerosis (ALS) and other neuromuscular diseases. It does so by funding worldwide research; by providing comprehensive health care services and support to MDA families nationwide; and by rallying communities to fight back through advocacy, fundraising and local engagement. Visit mda.org and follow us at facebook.com/MDAnational and @MDAnews.

SOURCE Muscular Dystrophy Association

RELATED LINKS
http://www.mdausa.org


Source: www.prnewswire.com

UK is 'addictions capital of Europe'

The UK is the "addictions capital of Europe" because of a failure to tackle the trade in "legal highs", heroin addiction and cheap alcohol, a think tank warns. For full post, click here.